SCHEMBL21296922

SCHEMBL21296922

CCOC(=O)c1nn[nH]c1Oc1ccc(C(CC)CC)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 1/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 4/20 0.37
POLB P06746 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GABRA1 P14867 2/20 0.36
GABRG2 P18507 2/20 0.36
GABRB3 P28472 2/20 0.36
GABRA5 P31644 2/20 0.36
GABRA3 P34903 2/20 0.36
GABRA2 P47869 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.35
HPGDS O60760 1/20 0.35
TARBP2 Q15633 2/20 0.34
PDCD4 Q53EL6 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21296877 0.86 HAO1 (0.39) ALDH1A1HDAC8HDAC6
SCHEMBL21296961 0.84 MAPT (0.45) KDM4EMAPTPOLBNPC1RAB9A
SCHEMBL21296921 0.84 MAPT (0.52) KDM4EMAPTPOLBNPC1RAB9A
SCHEMBL23001665 0.84 KDM4E (0.40) KDM4EMAPTPOLBNPC1RAB9A
SCHEMBL22795534 0.83 HPGDS (0.48) KDM4EMAPTPOLBNPC1RAB9A
SCHEMBL23001988 0.81 HAO1 (0.49) KDM4EMAPTPOLBNPC1RAB9A
SCHEMBL23001763 0.80 HAO1 (0.52) KDM4EGABRA1GABRG2GABRB3GABRA5
SCHEMBL23001817 0.78 GABRA1 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL23001812 0.76 HAO1 (0.54)
SCHEMBL23319974 0.75 JAK2 (0.46) KDM4EMAPTPOLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX NPBWR1 2573/4885KDM4E 3780/4885MAPT 1559/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX NPBWR1 2573/4885KDM4E 3780/4885MAPT 1559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.